Metabolomx awarded $1.14 million grant from NCI

Monday, October 24, 2011 01:34 PM

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, has been awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

Metabolomx' proprietary technology is designed to recognize the molecular fingerprint of lung cancer via a sampling of metabolites (volatile organic compounds) in exhaled breath. The company's system currently is being evaluated in a large lung cancer screening study at the Cleveland Clinic.

"We are grateful for the support of the NCI grant, which will help us to further validate our technology and advance the breakthrough studies of our breath analysis system for lung cancer, breast cancer, colon cancer and other cancers,” said Paul Rhodes, Ph.D., founder and CEO of Metabolomx.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs